INZY Live signals | Maximize Profits with Getagraph.com

SELL 102835 min ago

@ $5.52

Issued: 14 Feb 2024 @ 09:33

Return: -21.56%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.87 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	607 891
Average Volume	684 917
Market Cap	267.47M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.350 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.16
ATR14	$0.00600 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Treco Douglas A	Sell	25 000	Restricted Stock Units
2024-04-01	Treco Douglas A	Buy	25 000	Common Stock
2024-04-02	Treco Douglas A	Sell	7 523	Common Stock
2024-03-28	Winton Matthew	Buy	3 188	Common Stock
2024-03-13	Winton Matthew	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
97.96
Last 96 transactions
Buy: 18 900 467 \| Sell: 34 205 433

Volume Correlation

Long: 0.34 (neutral)

Short: 0.98 (very strong)

Signal:(75.875) Expect same movement, but be aware

Inozyme Pharma, Inc. Correlation

10 Most Positive Correlations
NAUT	0.951
SVFAU	0.95
AMTBB	0.945
WINA	0.943
TZPSU	0.941
BIOT	0.94
TZPS	0.937
COCO	0.937
SVFA	0.935
LMB	0.934

10 Most Negative Correlations
IPA	-0.947
WABC	-0.947
ISTR	-0.945
AROW	-0.945
BMRC	-0.945
BWB	-0.941
FVCB	-0.939
NFBK	-0.938
FLIC	-0.937
CVBF	-0.937

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inozyme Pharma, Inc. Correlation - Currency/Commodity

0.16
( neutral )

0.00
( neutral )

0.23
( neutral )

0.00
( neutral )

0.28
( neutral )

Inozyme Pharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.29M (0.00 %)
EPS:	$-1.370

Q4	2023
Revenue:	$0
Gross Profit:	$-306 000 (0.00 %)
EPS:	$-0.350

Q3	2023
Revenue:	$0
Gross Profit:	$-333 000 (0.00 %)
EPS:	$-0.290

Q2	2023
Revenue:	$0
Gross Profit:	$-331 000 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.